中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 7
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(7): 1704-1707

Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.07.048
  • 1.

    Department of Clinical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 2.

    Department of Clinical Laboratory, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

Research funding:

Luzhou Municipal People's Government & Southwest Medical University (2018LZXNYD-ZK08)

  • Received Date: 2020-12-02
  • Accepted Date: 2020-12-18
  • Published Date: 2021-07-20
    Abstract
  • Nonalcoholic fatty liver disease (NAFLD) is characterized by fatty degeneration, lipid metabolism disorders, and abnormal deposition in hepatocytes, and it has become the most prevalent liver disease in the world. The role of long non-coding RNAs (lncRNAs) in the development and progression of NAFLD has become a hotspot at present. This article summarizes the key lncRNAs in NAFLD, which are mainly involved in the regulation of the signaling pathways including lipid metabolism, glucose metabolism, and inflammatory changes, and elaborates on the mechanism of action of lncRNAs in promoting the development of NAFLD or its transformation to hepatitis and liver fibrosis. It is pointed out that in-depth on polygenomics and proteomics will promote the precise targeted therapy of NAFLD.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    YOUNOSSI Z, TACKE F, ARRESE M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682. DOI: 10.1002/hep.30251.
    [2]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [3]
    ATANASOVSKA B, RENSEN SS, van der SIJDE MR, et al. A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis[J]. Hepatology, 2017, 66(3): 794-808. DOI: 10.1002/hep.29034.
    [4]
    CHEN Q, XIONG C, JIA K, et al. Hepatic transcriptome analysis from HFD-fed mice defines a long noncoding RNA regulating cellular cholesterol levels[J]. J Lipid Res, 2019, 60(2): 341-352. DOI: 10.1194/jlr.M086215.
    [5]
    DANKO CG, HAH N, LUO X, et al. Signaling pathways differentially affect RNA polymerase Ⅱ initiation, pausing, and elongation rate in cells[J]. Mol Cell, 2013, 50(2): 212-222. DOI: 10.1016/j.molcel.2013.02.015.
    [6]
    GUO X, GAO L, WANG Y, et al. Advances in long noncoding RNAs: Identification, structure prediction and function annotation[J]. Brief Funct Genomics, 2016, 15(1): 38-46. DOI: 10.1093/bfgp/elv022.
    [7]
    HAN S, ZHANG T, KUSUMANCHI P, et al. Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease[J]. Clin Mol Hepatol, 2020, 26(4): 705-714. DOI: 10.3350/cmh.2020.0166.
    [8]
    KOPP F, MENDELL JT. Functional classification and experimental dissection of long noncoding RNAs[J]. Cell, 2018, 172(3): 393-407. DOI: 10.1016/j.cell.2018.01.011.
    [9]
    MACDONALD WA, MANN M. Long noncoding RNA functionality in imprinted domain regulation[J]. PLoS Genet, 2020, 16(8): e1008930. DOI: 10.1371/journal.pgen.1008930.
    [10]
    SUN C, LIU X, YI Z, et al. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease[J]. IUBMB Life, 2015, 67(11): 847-852. DOI: 10.1002/iub.1442.
    [11]
    CHEN Y, HUANG H, XU C, et al. Long non-coding RNA profiling in a non-alcoholic fatty liver disease rodent model: New insight into pathogenesis[J]. Int J Mol Sci, 2017, 18(1): 21. DOI: 10.3390/ijms18010021.
    [12]
    CHAO HW, CHAO SW, LIN H, et al. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2019, 20(2): 298. DOI: 10.3390/ijms20020298.
    [13]
    LIU J, TANG T, WANG GD, et al. lncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease[J]. Biosci Rep, 2019, 39(7): BSR20181722. DOI: 10.1042/BSR20181722.
    [14]
    WANG H, CAO Y, SHU L, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes[J]. J Cell Mol Med, 2020, 24(2): 1399-1412. DOI: 10.1111/jcmm.14818.
    [15]
    CHEN X, TAN XR, LI SJ, et al. lncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease[J]. Life Sci, 2019, 235: 116829. DOI: 10.1016/j.lfs.2019.116829.
    [16]
    SUN Y, SONG Y, LIU C, et al. lncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling[J]. Biochem Biophys Res Commun, 2019, 516(2): 584-590. DOI: 10.1016/j.bbrc.2019.06.104.
    [17]
    ZHANG M, CHI X, QU N, et al. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis[J]. Biochem Biophys Res Commun, 2018, 499(1): 66-70. DOI: 10.1016/j.bbrc.2018.03.127.
    [18]
    CHEN Y, CHEN X, GAO J, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway[J]. FASEB J, 2019, 33(10): 11411-11419. DOI: 10.1096/fj.201900643RRR.
    [19]
    CHEN G, YU D, NIAN X, et al. lncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL)[J]. Sci Rep, 2016, 6: 35531. DOI: 10.1038/srep35531.
    [20]
    ZHU X, WU YB, ZHOU J, et al. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression[J]. Biochem Biophys Res Commun, 2016, 469(2): 319-325. DOI: 10.1016/j.bbrc.2015.11.048.
    [21]
    HUANG P, HUANG FZ, LIU HZ, et al. lncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6[J]. Metabolism, 2019, 94: 1-8. DOI: 10.1016/j.metabol.2019.01.018.
    [22]
    WANG J, YANG W, CHEN Z, et al. Long noncoding RNA lncSHGL recruits hnRNPA1 to suppress hepatic gluconeogenesis and lipogenesis[J]. Diabetes, 2018, 67(4): 581-593. DOI: 10.2337/db17-0799.
    [23]
    ZHAO XY, LI S, DELPROPOSTO JL, et al. The long noncoding RNA Blnc1 orchestrates homeostatic adipose tissue remodeling to preserve metabolic health[J]. Mol Metab, 2018, 14: 60-70. DOI: 10.1016/j.molmet.2018.06.005.
    [24]
    TANG S, ZHU W, ZHENG F, et al. The long noncoding RNA Blnc1 protects against diet-induced obesity by promoting mitochondrial function in white fat[J]. Diabetes Metab Syndr Obes, 2020, 13: 1189-1201. DOI: 10.2147/DMSO.S248692.
    [25]
    ZHAO XY, XIONG X, LIU T, et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis[J]. Nat Commun, 2018, 9(1): 2986. DOI: 10.1038/s41467-018-05383-2.
    [26]
    DONG Z, LI S, WANG X, et al. lncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 316(4): G539-G550. DOI: 10.1152/ajpgi.00249.2018.
    [27]
    SHEN X, GUO H, XU J, et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease[J]. J Cell Physiol, 2019, 234(10): 18169-18179. DOI: 10.1002/jcp.28450.
    [28]
    YAN C, CHEN J, CHEN N. Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability[J]. Sci Rep, 2016, 6: 22640. DOI: 10.1038/srep22640.
    [29]
    MALAKAR P, STEIN I, SARAGOVI A, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2[J]. Cancer Res, 2019, 79(10): 2480-2493. DOI: 10.1158/0008-5472.CAN-18-1432.
    [30]
    LETI F, LEGENDRE C, STILL CD, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells[J]. Transl Res, 2017, 190: 25-39.e21. DOI: 10.1016/j.trsl.2017.09.001.
    [31]
    BU FT, WANG A, ZHU Y, et al. lncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases[J]. Liver Int, 2020, 40(11): 2612-2626. DOI: 10.1111/liv.14629.
    [32]
    WANG X. Down-regulation of lncRNA-NEAT1 alleviated the non-alcoholic fatty liver disease via mTOR/S6K1 signaling pathway[J]. J Cell Biochem, 2018, 119(2): 1567-1574. DOI: 10.1002/jcb.26317.
    [33]
    CHI Y, GONG Z, XIN H, et al. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway[J]. J Transl Med, 2020, 18(1): 126. DOI: 10.1186/s12967-020-02225-y.
    [34]
    CHOONIEDASS-KOTHARI S, VINCETT D, YAN Y, et al. The protein encoded by the functional steroid receptor RNA activator is a new modulator of ER alpha transcriptional activity[J]. FEBS Lett, 2010, 584(6): 1174-1180. DOI: 10.1016/j.febslet.2010.02.024.
    [35]
    CHAKRABARTI P, KANDROR KV. FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes[J]. J Biol Chem, 2009, 284(20): 13296-13300. DOI: 10.1074/jbc.C800241200.
    [36]
    CHUNHAROJRITH P, NAKAYAMA Y, JIANG X, et al. Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line[J]. Mol Cell Endocrinol, 2015, 416: 27-35. DOI: 10.1016/j.mce.2015.08.018.
    [37]
    WANG X, WANG J. High-content hydrogen water-induced downregulation of miR-136 alleviates non-alcoholic fatty liver disease by regulating Nrf2 via targeting MEG3[J]. Biol Chem, 2018, 399(4): 397-406. DOI: 10.1515/hsz-2017-0303.
    [38]
    WANG Y, JING W, MA W, et al. Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma[J]. Cancer Biomark, 2018, 22(2): 227-236. DOI: 10.3233/CBM-170781.
    [39]
    XIONG H, LI B, HE J, et al. lncRNA HULC promotes the growth of hepatocellular carcinoma cells via stabilizing COX-2 protein[J]. Biochem Biophys Res Commun, 2017, 490(3): 693-699. DOI: 10.1016/j.bbrc.2017.06.103.
    [40]
    PENG H, WANG J, LI J, et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer[J]. Life Sci, 2016, 151: 235-242. DOI: 10.1016/j.lfs.2016.03.002.
    [41]
    SOOKOIAN S, FLICHMAN D, GARAYCOECHEA ME, et al. Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage[J]. Hepatol Commun, 2018, 2(6): 654-665. DOI: 10.1002/hep4.1184.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (671) PDF downloads(56) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return